(Q59798588)

12 December 2020

Regulation of ubiquitin-dependent processes by deubiquitinating enzymes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Chemical genetic control of protein levels: selective in vivo targeted degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Protein aggregation and neurodegenerative disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Proteolysis: from the lysosome to ubiquitin and the proteasome

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Targeted protein degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

RING domain E3 ubiquitin ligases

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Recognition and processing of ubiquitin-protein conjugates by the proteasome

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Breaking the chains: structure and function of the deubiquitinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Emerging roles of deubiquitinases in cancer-associated pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Trends in the exploitation of novel drug targets

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Deubiquitinases in cancer: new functions and therapeutic options.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/30486612

1 reference

12 December 2020

Inhibitor mediated protein degradation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Deubiquitylases from genes to organism

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Emerging therapies targeting the ubiquitin proteasome system in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Pharmacological targeting of the pseudokinase Her3

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Ubiquitination in disease pathogenesis and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Novel selection methods for DNA-encoded chemical libraries

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

USP30 deubiquitylates mitochondrial Parkin substrates and restricts apoptotic cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Catalytic in vivo protein knockdown by small-molecule PROTACs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Deubiquitinases (DUBs) and DUB inhibitors: a patent review

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Degradation of Akt using protein-catalyzed capture agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Drugging the undruggables: exploring the ubiquitin system for drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Chemical and semisynthetic approaches to study and target deubiquitinases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Induced protein degradation: an emerging drug discovery paradigm

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Proteasome inhibitors in cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Targeted protein degradation by PROTACs

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Waste disposal-An attractive strategy for cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Deubiquitylating enzymes and drug discovery: emerging opportunities.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Meddling with Fate: The Proteasomal Deubiquitinating Enzymes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

USP7 small-molecule inhibitors interfere with ubiquitin binding

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Discovery and characterization of highly potent and selective allosteric USP7 inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase using PROTAC-mediated Degradation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Development of the first small molecule histone deacetylase 6 (HDAC6) degraders

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020

Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30486612

12 December 2020